Outsourced Pharma Capabilities Update May 2026: Combination Products & Drug Delivery

The move toward self-administered, home-based treatments has made drug–device combination products a strategic priority. Success now requires tight integration across formulation, device design, testing, human factors, and regulatory strategy—not separate workflows.

This session outlines the key decisions and capabilities for successful programs, including choosing platform vs. custom devices, ensuring formulation–device compatibility, and meeting testing standards. It also covers regulatory expectations, human factors validation, and scaling manufacturing for autoinjectors and wearables—plus how early planning and emerging digital strategies can reduce risk and accelerate development.